Skip to content

Tarsus Pharmaceuticals, Inc. TARS Change in receivables

Change in receivables at other companies

NNN REIT logo
NNN REITNNN
$335K-44.4%
Unifirst logo
UnifirstUNF
$8.48M+135%
Cabot Corporation logo
Cabot CorporationCBT
-$64M-256%
LKQ logo
LKQLKQ
$271M+5.9%
Workiva logo
WorkivaWK
-$2.44M-145%
Knife River logo
Knife RiverKNF
-$52.55M-27.9%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s change in receivables?
Tarsus Pharmaceuticals, Inc. (TARS) reported change in receivables of -$189K in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s change in receivables changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s change in receivables decreased by 144.1% year-over-year, from $429K to -$189K.
What does change in receivables mean?
Change in total receivables including trade and non-trade receivables.